Physician profile
Cory A Cunningham
NPI 1932271913
$2,733.54
in general payments reported to CMS, 2019-2025
26 companies · $478 in 2025
The $478 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $538 · 2022: $696 · 2023: $611 · 2024: $411 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,499.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $520.23 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Novo Nordisk INC | $483.60 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $449.49 | 2021-2024 | |
| Amgen INC. | $159.50 | 2021-2024 | Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.11 | 2021-2023 | Xifaxan |
| Abbott Laboratories | $115.00 | 2022-2023 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $109.18 | 2021-2022 | |
| Pfizer INC. | $106.92 | 2021-2025 | |
| Organon LLC | $100.67 | 2025 | Nexplanon |
| Astrazeneca Pharmaceuticals LP | $84.56 | 2021-2024 | Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $67.02 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $65.27 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $51.39 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $37.21 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.17 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.73 | 2021 | |
| Corcept Therapeutics | $31.90 | 2025 | Korlym |
| Janssen Pharmaceuticals, INC | $23.67 | 2025 | Spravato |
| Vanda Pharmaceuticals INC. | $21.82 | 2021 | |
| Seqirus USA INC | $21.77 | 2024 | Flucelvax, Fluad |
| Qiagen, LLC | $21.30 | 2021 | |
| Amarin Pharma, INC. | $17.35 | 2021 | |
| Currax Pharmaceuticals LLC | $15.30 | 2024 | Contrave, Onzetra Xsail |
| Esperion Therapeutics, INC. | $15.25 | 2021 | |
| Sanofi Pasteur INC. | $13.11 | 2023 | |
| Bausch Health US, LLC | $13.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.